Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

NCT02201940 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

741

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus Infection

Interventions

DRUG: SOF/VEL
DRUG: Placebo

Sponsor

Gilead Sciences